Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/16/2883266/0/en/Tourmaline-Bio-Initiates-Clinical-Development-of-TOUR006-for-Cardiovascular-Diseases-with-First-Patient-Dosed-in-Phase-2-TRANQUILITY-Trial.html
https://www.globenewswire.com/news-release/2024/05/13/2880265/0/en/Tourmaline-Bio-Reports-First-Quarter-2024-Financial-Results-and-Recent-Business-Highlights.html
https://www.globenewswire.com/news-release/2024/03/19/2848416/0/en/Tourmaline-Bio-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Business-Highlights.html
https://www.globenewswire.com//news-release/2024/02/27/2835888/0/en/Tourmaline-Bio-to-Present-at-Upcoming-Investor-Conferences.html
https://www.globenewswire.com//news-release/2024/02/01/2821941/0/en/Tourmaline-Bio-to-Present-at-the-Guggenheim-Healthcare-Talks-6th-Annual-Biotechnology-Conference.html
https://www.globenewswire.com/news-release/2024/01/29/2819419/0/en/Tourmaline-Bio-Announces-Closing-of-172-5-Million-Public-Offering-of-Common-Stock-Including-Full-Exercise-of-the-Underwriters-Option-to-Purchase-Additional-Shares.html
https://www.globenewswire.com//news-release/2024/01/25/2816562/0/en/Tourmaline-Bio-Announces-Pricing-of-Public-Offering-of-Common-Stock.html
https://www.globenewswire.com//news-release/2024/01/24/2816077/0/en/Tourmaline-Bio-Announces-Proposed-Public-Offering-of-Common-Stock.html
https://www.globenewswire.com//news-release/2024/01/08/2805285/0/en/Tourmaline-Bio-Announces-Expected-Upcoming-Key-Milestones-for-the-Clinical-Development-of-TOUR006-a-Long-Acting-Subcutaneous-Inhibitor-of-IL-6-with-Best-in-Class-Potential-in-Thyro.html
https://www.globenewswire.com//news-release/2023/12/15/2797271/0/en/Tourmaline-Bio-added-to-the-NASDAQ-Biotechnology-Index.html